Biologically Intelligent Database Searching for Lead Identification and Patent Fortification

Cresset, the innovative provider of chemistry software and services, has announced the completion of its Cresset proV10 suite with the relaunch of its highly successful FieldScreen system as blazeV10 for ligand based virtual screening. blazeV10 uses the shape and electrostatic character of known ligands to rapidly search large chemical collections for molecules with similar properties, returning diverse new leads. This makes it a powerful tool for patent fortification and compound reprofiling.

blazeV10 is used to find biologically active molecules in a wide range of situations across the pharmaceutical, agrochemical and fine chemical industries. Using blazeV10 for virtual screening before a wet screening run can dramatically increase the hit rate, cutting costs and speeding up the discovery process. Applying blazeV10 to HTS results finds molecules which falsely failed the biological assay, rescuing them for further investigation. Using blazeV10 on compounds of known biological activity provides insights into off-target effects. Employing blazeV10 to search databases of known drugs identifies potential re-profiling opportunities. Cresset consultants use blazeV10 to advise clients on how to strengthen their patent position by identifying structurally diverse compounds that could be potential fast followers.

Dr Robert Scoffin, CEO of Cresset, says, “The relaunch of one of our leading applications as blazeV10 completes the rebranding of the Cresset range of software for molecular design and discovery. blazeV10, sparkV10, torchV10 and forgeV10 are outstanding tools that help chemists design and discover the best new active molecules for life science research.”

blazeV10 is operated through a simple web-based wizard like interface or as a series of command line applications and is available as software for installation, software as a service running on cloud hardware, or through consultancy with Cresset’s project services team.